²²⁵Ac-FPI-2068 is a targeted Alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that express EGFR and cMET. EGFR and cMET are both validated targets that are co-expressed in multiple tumor types, including head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. This drug will be paired with the Imaging agent ¹¹¹In-FPI-2107.

In April 2023, FDA has cleared the IND applications for ²²⁵Ac-FPI-2068 and the corresponding Imaging analogue ¹¹¹In-FPI-2107.

Target/Mechanism: EGFR

Carrier/Ligand: Fab

Radiation Type: Alpha particle (α)